Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CALCIPOTRIOL

All products: Limited Use (codes 191)

Other products in the same Health Canada class (D05AX) — coverage varies; not interchangeable

  • Calcitriol (Silkis): limited Use 191

Dovonex · DIN 01976133 · 50mcg/g · Oint

Limited Use — Reason for Use code 191 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 191 required
Write on scriptLU code 191 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 191
Reason for Use code 191 For the treatment of psoriasis in patients who have failed topical corticosteroids alone, or are intolerant to topical corticosteroids. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Dovonex · DIN 01976133 Manufacturer: Leo Pharma Inc.; listing date 1997-04-10 Health Canada: Marketed since 1992-12-31 · brand DOVONEX · ATC D05AX02 CALCIPOTRIOL · form Ointment · route Topical · ingredients CALCIPOTRIOL 50 MCG/G · company Leo pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Dovonex: Formulary list price $1.2489/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.2489 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13340 · Verify on the e-Formulary ↗ (DIN 01976133)

Source record
DIN 01976133: Dovonex Raw flags: sec12=Y, sec3=Y Item: 843600044; group id 859; item number 2080; lccId 00119; manufacturer id LEO Source form: Oint; strength: 50mcg/g Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.2489; ministry $1.2489 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01976133 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13340
Shortage status: resolved shortage (ended 2022-11-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01976133
Shortage record checked 2026-09-13T08:10:21.292534+00:00

CALCIPOTRIOL & BETAMETHASONE DIPROPIONATE

Form:

5 of 5 products shown

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (D05AX) — coverage varies; not interchangeable

  • Calcitriol (Silkis): limited Use 191

Dovobet · DIN 02244126 · 50mcg/g & 0.5mg/g · Oint

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Dovobet · DIN 02244126 Manufacturer: Leo Pharma Inc.; listing date 2008-05-16 Health Canada: Marketed since 2001-11-29 · brand DOVOBET OINTMENT · ATC D05AX52 CALCIPOTRIOL, COMBINATIONS, D05AX52 CALCIPOTRIOL, COMBINATIONS · form Ointment · route Topical · ingredients CALCIPOTRIOL 50 MCG/G, BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.5 MG/G · company Leo pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $1.2545 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68084 · Verify on the e-Formulary ↗ (DIN 02244126)

Source record
DIN 02244126: Dovobet Raw flags: sec3=Y Item: 840600151; group id 840; item number 2043; lccId None; manufacturer id LEO Source form: Oint; strength: 50mcg/g & 0.5mg/g Recorded listing: General benefit Source prices (unrounded): $2.1918; ministry $1.2545 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02244126 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68084 Therapeutic Notes (formulary) Note: For use in patients with psoriasis who have failed 1st line topical steroids and Dovonex (calcipotriol) therapy.
Interchangeable products
Teva-Betamethasone/Calcipotriol · DIN 02427419 · $1.2545
Shortage status: resolved shortage (ended 2018-10-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02244126
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Betamethasone/Calcipotriol · DIN 02427419 · 50mcg/g & 0.5mg/g · Oint

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Betamethasone/Calcipotriol · DIN 02427419 Manufacturer: Teva Canada Limited; listing date 2021-04-30 Health Canada: Marketed since 2020-08-07 · brand TEVA-BETAMETHASONE/ CALCIPOTRIOL · ATC D07XC01 BETAMETHASONE, D07XC01 BETAMETHASONE · form Ointment · route Topical · ingredients CALCIPOTRIOL 50 MCG/G, BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.5 MG/G · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Betamethasone/Calcipotriol: Formulary list price $1.2545/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.2545 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91194 · Verify on the e-Formulary ↗ (DIN 02427419)

Source record
DIN 02427419: Teva-Betamethasone/Calcipotriol Raw flags: sec3=Y Item: 840600151; group id 840; item number 2043; lccId None; manufacturer id TEV Source form: Oint; strength: 50mcg/g & 0.5mg/g Recorded listing: General benefit Source prices (unrounded): $1.2545; ministry $1.2545 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02427419 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91194 Therapeutic Notes (formulary) Note: For use in patients with psoriasis who have failed 1st line topical steroids and Dovonex (calcipotriol) therapy.
Interchangeable products
Dovobet · DIN 02244126 · $1.2545
Shortage status: active shortage (reported 2025-12-03, last updated 2026-07-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02427419
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Enstilar · DIN 02457393 · 50mcg/g & 0.5mg/g · Top Aero Foam

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Enstilar · DIN 02457393 Manufacturer: Leo Pharma Inc.; listing date 2018-10-31 Health Canada: Marketed since 2016-11-11 · brand ENSTILAR · ATC D05AX52 CALCIPOTRIOL, COMBINATIONS, D05AX52 CALCIPOTRIOL, COMBINATIONS · form Aerosol (foam) · route Topical · ingredients BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.5 MG/G, CALCIPOTRIOL (CALCIPOTRIOL MONOHYDRATE) 50 MCG/G · company Leo pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Enstilar: Formulary list price $1.6412/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.6412 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94445 · Verify on the e-Formulary ↗ (DIN 02457393)

Source record
DIN 02457393: Enstilar Raw flags: sec3=Y Item: 840600154; group id 840; item number 2044; lccId None; manufacturer id LEO Source form: Top Aero Foam; strength: 50mcg/g & 0.5mg/g Recorded listing: General benefit Source prices (unrounded): $1.6412; ministry $1.6412 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02457393 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94445 Therapeutic Notes (formulary) For the treatment of moderate to severe scalp psoriasis in patients who have failed first-line topical corticosteroid therapy. For the treatment of mild to moderate body psoriasis in patients who have failed first-line topical corticosteroid therapy and Dovonex (calcipotriol) therapy.
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02457393
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Dovobet Gel · DIN 02319012 · 50mcg/g & 0.5mg/g · Top Gel

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Dovobet Gel · DIN 02319012 Manufacturer: Leo Pharma Inc.; listing date 2011-05-19 Health Canada: Marketed since 2012-10-12 · brand DOVOBET GEL · ATC D05AX52 CALCIPOTRIOL, COMBINATIONS, D05AX52 CALCIPOTRIOL, COMBINATIONS · form Gel · route Topical · ingredients BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.5 MG/G, CALCIPOTRIOL (CALCIPOTRIOL MONOHYDRATE) 50 MCG/G · company Leo pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $1.3142 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80450 · Verify on the e-Formulary ↗ (DIN 02319012)

Source record
DIN 02319012: Dovobet Gel Raw flags: sec3=Y Item: 840600152; group id 840; item number 2045; lccId None; manufacturer id LEO Source form: Top Gel; strength: 50mcg/g & 0.5mg/g Recorded listing: General benefit Source prices (unrounded): $2.1867; ministry $1.3142 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02319012 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80450 Therapeutic Notes (formulary) Notes: For the treatment of moderate to severe scalp psoriasis in patients who have failed first-line topical corticosteroid therapy. For the treatment of mild to moderate body psoriasis in patients who have failed first-line topical corticosteroid therapy and Dovonex (calcipotriol) therapy.
Interchangeable products
Taro-Calcipotriol / Betamethasone Gel · DIN 02525178 · $1.3142
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02319012
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Taro-Calcipotriol / Betamethasone Gel · DIN 02525178 · 50mcg/g & 0.5mg/g · Top Gel

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Taro-Calcipotriol / Betamethasone Gel · DIN 02525178 Manufacturer: Taro Pharmaceuticals Inc.; listing date 2022-06-30 Health Canada: Marketed since 2022-06-01 · brand TARO-CALCIPOTRIOL / BETAMETHASONE GEL · ATC D05AX52 CALCIPOTRIOL, COMBINATIONS, D05AX52 CALCIPOTRIOL, COMBINATIONS · form Gel · route Topical · ingredients CALCIPOTRIOL (CALCIPOTRIOL MONOHYDRATE) 50 MCG/G, BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.5 MG/G · company Taro pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Taro-Calcipotriol / Betamethasone Gel: Formulary list price $1.3142/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.3142 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101421 · Verify on the e-Formulary ↗ (DIN 02525178)

Source record
DIN 02525178: Taro-Calcipotriol / Betamethasone Gel Raw flags: sec3=Y Item: 840600152; group id 840; item number 2045; lccId None; manufacturer id TAR Source form: Top Gel; strength: 50mcg/g & 0.5mg/g Recorded listing: General benefit Source prices (unrounded): $1.3142; ministry $1.3142 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02525178 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101421 Therapeutic Notes (formulary) Notes: For the treatment of moderate to severe scalp psoriasis in patients who have failed first-line topical corticosteroid therapy. For the treatment of mild to moderate body psoriasis in patients who have failed first-line topical corticosteroid therapy and Dovonex (calcipotriol) therapy.
Interchangeable products
Dovobet Gel · DIN 02319012 · $1.3142
Shortage status: resolved shortage (ended 2026-02-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02525178
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary classes and how they are covered

Other drugs in the same formulary class (84:06 Anti-Inflammatory) and how they are covered

Matched class: 84:06 Anti-Inflammatory

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BECLOMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE IN A BASE CONTAINING PROPYLENE GLYCOL, BETAMETHASONE DIPROPIONATE IN PROPYLENE GLYCOL BASE, HALOBETASOL PROPIONATE, MOMETASONE FUROATE Some products covered without a code (check the product listing): AMCINONIDE, BETAMETHASONE DIPROPIONATE, BETAMETHASONE VALERATE, CLOBETASOL PROPIONATE, DESONIDE, FLUOCINONIDE, HYDROCORTISONE, HYDROCORTISONE ACETATE, HYDROCORTISONE VALERATE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE 0.1% IN ORABASE 84:06 Anti-Inflammatory

AMCINONIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 0.1% · Cr

BECLOMETHASONE DIPROPIONATE

· 2 products · General benefit · strengths: 0.025% · Cr, Oint

BETAMETHASONE DIPROPIONATE

· 6 products · General benefit (5), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 0.05% · Cr, Lot, Oint

BETAMETHASONE DIPROPIONATE IN A BASE CONTAINING PROPYLENE GLYCOL

· 2 products · General benefit · strengths: 0.05% · Oint

BETAMETHASONE DIPROPIONATE IN PROPYLENE GLYCOL BASE

· 2 products · General benefit · strengths: 0.05% · Cr

BETAMETHASONE VALERATE

· 19 products · Listed, not a benefit (7), General benefit (12) · strengths: 0.05%, 0.1% · Cr, Lot, Oint, Scalp Lot

CLOBETASOL PROPIONATE

· 20 products · General benefit (11), Off-Formulary Interchangeable, not an ODB benefit (9) · strengths: 0.05%, 0.05% w/w · Cr, Oint, Scalp Lot, Top Shampoo, Top Sol Sp

DESONIDE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 0.05% · Cr, Oint

FLUOCINONIDE

· 8 products · General benefit (4), Listed, not a benefit (4) · strengths: 0.05% · Cr, Emol Cr, Gel, Oint

HALOBETASOL PROPIONATE

· 1 products · General benefit · strengths: 0.01% w/w · Lot

HYDROCORTISONE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 0.5%, 1% · Oint

HYDROCORTISONE ACETATE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 1% · Cr Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 84:06 and 5 more
Full class listing Related classes: 84:04 Anti-Infectives, 84:28 Keratolytic Agents, 84:36 Miscellaneous Skin and Mucous Membrane Agents

Other drugs in the same formulary class (84:36 Miscellaneous Skin and Mucous Membrane Agents) and how they are covered

Matched class: 84:36 Miscellaneous Skin and Mucous Membrane Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ACITRETIN, AZELAIC ACID, FLUOROURACIL, ISOTRETINOIN, ZINC SULFATE Some products covered without a code (check the product listing): COLLAGENASE 84:36 Miscellaneous Skin and Mucous Membrane Agents

CALCITRIOL

· 1 products · Limited Use, codes 191 · strengths: 3mcg/g · Oint

ACITRETIN

· 6 products · General benefit · strengths: 10mg, 25mg · Cap

AZELAIC ACID

· 1 products · General benefit · strengths: 15% · Top Gel

COLLAGENASE

· 2 products · General benefit (1), Temporary benefit (1) · strengths: 250Unit/g · 30g Pk, Oint-30g Pk

FLUOROURACIL

· 1 products · General benefit · strengths: 5% · Cr

ISOTRETINOIN

· 8 products · General benefit · strengths: 10mg, 20mg, 30mg, 40mg · Cap

ZINC SULFATE

· 2 products · General benefit · strengths: 0.5%, 10mg · Oint, Sup

ALITRETINOIN

· 4 products · Listed, not a benefit (2), Limited Use, codes 442 (2) · strengths: 10mg, 30mg · Cap

BRODALUMAB

· 1 products · Limited Use, codes 553 · strengths: 210mg/1.5mL · Inj Sol-Pref Syr

IXEKIZUMAB

· 2 products · Limited Use, codes 526 · strengths: 80mg/mL · Inj Sol-Pref Autoinj, Inj Sol-Pref Syr

PIMECROLIMUS

· 1 products · Limited Use, codes 383 · strengths: 1% · Cr

RISANKIZUMAB

· 3 products · Limited Use, codes 574 · strengths: 75mg/0.83mL, 150mg/mL · Inj Sol-0.83mL Pref Syr (Preservative-Free), Inj Sol-Pref Pen (Preservative-Free), Inj Sol-Pref Syr (Preservative-Free) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 84:36 and 3 more
Full class listing Related classes: 84:04 Anti-Infectives, 84:06 Anti-Inflammatory, 84:28 Keratolytic Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
Product monograph unavailable: download failed: DPDUnavailable
What the Health Canada label says it is for
1. Indications DOVOBET (calcipotriol and betamethasone dipropionate) ointment is indicated for: • the topical treatment of psoriasis vulgaris for up to 4 weeks. 1.1. Pediatrics Pediatrics (< 18 years): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2. Geriatrics Geriatrics (≥ 65 years): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for geriatric use. https://pdf.hres.ca/dpd_pm/00085846.PDF PM date: 2026-08-21 Source product: DOVOBET OINTMENT; DIN 02244126; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Teva-Betamethasone/Calcipotriol · DIN 02427419 Shortage status: active shortage (reported 2025-12-03, last updated 2026-07-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02427419

Check this DIN again